In the last trading session, 3,769,140 shares of the Baudax Bio, Inc.(NASDAQ:BXRX) were traded, and its beta was 0. Most recently the company’s share price was $1.68, and it changed around $0.09 or 0.06% from the last close, which brings the market valuation of the company to $117.84 Million. BXRX currently trades at a discount to its 52-week high of $9.6, offering almost -471.43% off that amount. The share price’s 52-week low was $0.97, which indicates that the current value has risen by an impressive 42.26% since then. We note from Baudax Bio, Inc.’s average daily trading volume that its 10-day average is 7.8 Million shares, with the 3-month average coming to 6.14 Million.
Baudax Bio, Inc. stock received a consensus recommendation rating of Buy, based on a mean score of 1.7. If we narrow it down even further, the data shows that none out of 3 analysts rate the stock as a Sell; another but none rate it as Overweight. Among the rest, no body recommended BXRX as a Hold, whereas 3 deemed it a Buy, and no one rated it as Underweight. Baudax Bio, Inc. is expected to report earnings per share of -$0.19 for the current quarter.
Baudax Bio, Inc. (NASDAQ:BXRX): Trading Information
Instantly BXRX has showed a green trend with a performance of 5.66% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of $2.06 on Friday, Feb 12 increased the stock’s daily price by 18.45%. The company’s shares are currently up 0.66% year-to-date, but still down -0.0968 over the last five days. On the other hand, Baudax Bio, Inc. (NASDAQ:BXRX) is 0.14% up in the 30-day period. We can see from the shorts that 3.03 Million shares have been sold at a short interest cover period of 0.49 day(s).
The consensus price target as assigned by Wall Street analysts is $4.67, which translates to bears needing to increase their stock price by 177.98% from its current value. Analyst projections state that BXRX is forecast to be at a low of $3 and a high of $6. In order for the stock price to hit the forecast high, the stock would need to surge +257.14% from its current level, while the stock would need to crash 78.57% from its current level to reach the projected low.
Baudax Bio, Inc. (BXRX) projections and forecasts
Baudax Bio, Inc. share prices are not performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -42.27 percent over the past six months and at a -80.66% annual growth rate that is well below the industry average of 17.3%. Moreover, analysts have decided to roll up on their fiscal year 2021 revenue estimates. The rating firms predict that it will gain +95.3% in revenue this quarter, and will report an increase of 90.7% in the next quarter. The year-over-year growth rate is expected to be 2218.5%, up from the previous year.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of 0%. Baudax Bio, Inc. earnings are expected to decrease by -12.9% in 2021, but the outlook is negative 0% per year for the next five years.
Baudax Bio, Inc. (NASDAQ:BXRX)’s Biggest Investors
Upon looking at major shareholders, it appears that insiders hold 0.51% of Baudax Bio, Inc. shares, and 18.96% of them are in the hands of institutional investors. The stock currently has a share float of 19.06%. Baudax Bio, Inc. stock is held by 50 institutions, with North Run Capital LP being the largest institutional investor. By Sep 29, 2020, it held 2.63% of the shares, which is about 1.01 Million shares worth $2.8 Million.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Corsair Capital Management, L.P., with 1.13% or 432.75 Thousand shares worth $1.2 Million as of Sep 29, 2020, holds the second largest percentage of outstanding shares.